Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib + Rituximab/Obinutuzumab in R/R FL and MZL (CITADEL-302)
NCT04796922Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Dec 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and marginal zone lymphoma (MZL) comparing Parsaclisib + Anti-CD20 with Placebo + Anti-CD20 (2 arms). Primary endpoint: Progression Free Survival at 62 months. Planned start Dec 2022; status: withdrawn.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04796922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796922.